Clinical trials: Bone Loss, Postmenopausal
Hearing Loss, Osteoporosis, Postmenopausal
Hearing Loss and Osteoporosis
To compare the audiological profiles in postmenopausal women with and without osteoporosis and to examine the pattern of hearing loss in osteoporotic patients.
- Trial name
- NCT03895333
- Testing
- Audiological profiling and bone mineral densitometry measurement
- Where
- Turkey (Türkiye)
- Volunteers
- 160 people
- Sponsor
- Kanuni Sultan Suleyman Training and Research Hospital
Post-menopausal Osteoporosis
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Doses of PTH134 in Post-menopausal Women
This study is designed to provide information about the bone-anabolic response of PTH134 when administered orally, in comparison to Forsteo®, the sub-cutaneous form of teriparatide, the active ingredient in PTH134.
- Trial name
- NCT01224717
- Testing
- PTH134, Forsteo
- Where
- 4 sites in Denmark, Germany
- Volunteers
- 104 people
- Sponsor
- Novartis
Postmenopausal Women With Osteoporosis
Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis
The purpose of this study is to determine if treatment is effective in preventing fractures in women with postmenopausal osteoporosis.
- Trial name
- ARCH (NCT01631214)
- Testing
- Romosozumab, Alendronate
- Where
- 316 sites in United States, Argentina and 40 more
- Volunteers
- 4,093 people
- Sponsor
- Amgen
Periodontal Disease, Postmenopausal Osteoporosis (PMO)
Relationship Between Periodontal Disease and Postmenopausal Osteoporosis
Elevated sclerostin levels in serum and alveolar bone of osteoporotic patients may exert deleterious effects on the periodontium, thereby contributing to the progression and increased severity of periodontal disease.
- Trial name
- NCT07294105
- Testing
- clinical assessment, Radiographic Evaluation
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Recep Tayyip Erdogan University
Osteoporosis, Post-Menopausal
Carotid Artery Intima-Media Thickness Following Exposure to Raloxifene or Placebo
The purpose of this study is to measure carotid artery IMT at a single visit in a subset of women previously enrolled in the CORE (H3S-MC-GGJY) trial
- Trial name
- NCT00532246
- Testing
- raloxifene
- Where
- 5 sites in United States
- Volunteers
- 147 people
- Sponsor
- Eli Lilly and Company
Bariatric Surgery in Postmenopausal Women
Bone Marrow Fat and Bariatric Surgery-Mediated Bone Loss
Results are inconsistent and further studies are needed to better understand the impact of bariatric surgery on the bone-BMA relationship depending on the type of bariatric surgery: RYGB vs. SG.
- Trial name
- ADIMOS-OB (NCT05005039)
- Where
- France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Lille
Postmenopausal Osteoporosis
Study of Post Menopausal Osteoporosis (PMO) Among Gynecology Outpatients in Pakistan
This observational study will provide an opportunity to document local patterns of susceptibility, patient profile, and usefulness of screening in postmenopausal patients coming to gynecology outpatient clinics in Pakistan.
- Trial name
- NCT02422069
- Where
- 8 sites in Pakistan
- Volunteers
- 624 people
- Sponsor
- Hoffmann-La Roche
Osteoporosis, Postmenopausal
A Study to Evaluate Alendronate Sodium /Vitamin D3 Combination Tablets(FOSAMAX PLUS) Versus Calcitriol in the Treatment of Osteoporosis in Postmenopausal Women in China (MK-0217A-264)
This study will evaluate whether the once weekly administration of the combination tablet alendronate/vitamin D3 (FOSAMAX PLUS) will increase lumbar spine bone mineral density (BMD) more than the daily use of calcitriol.
- Trial name
- NCT01350934
- Testing
- alendronate 70-mg/vitamin D3 5600 IU combination tablet (Fosamax Plus), Calcitriol, Calcium 500 mg
- Volunteers
- 219 people
- Sponsor
- Organon and Co
Osteoporosis
Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density
This study will compare the effects of Zoledronic acid and Raloxifene in reducing bone turnover markers in postmenopausal women with low bone mineral density over 6 months.
- Trial name
- NCT00431444
- Testing
- Raloxifene, Zoledronic acid
- Where
- 17 sites in United States
- Volunteers
- 110 people
- Sponsor
- Novartis
Osteoporosis
Weekly vs Daily Teriparatide Therapy in Severe Postmenopausal Osteoporosis
Osteoporosis is characterized by decreased bone strength and it is prevalent among postmenopausal women but also occurs in men and women with underlying conditions or major risk factors associated with bone demineralization.
- Trial name
- NCT01760798
- Testing
- Teriparatide
- Where
- India
- Volunteers
- 20 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Osteoporosis, Postmenopausal
A Study to Compare the Efficacy of Alendronate With and Without Calcium or Calcium Alone In the Treatment of Osteoporosis in Postmenopausal Women (0217-088)(COMPLETED)
The purpose of this study is to see how well alendronate and calcium as compared to calcium alone increase bone density in postmenopausal women with osteoporosis
- Trial name
- NCT00398606
- Testing
- MK0217, alendronate sodium / Duration of Treatment : 2 Years, Comparator : calcium carbonate /Duration of Treatment : 2 Years
- Volunteers
- 650 people
- Sponsor
- Organon and Co
Osteoporosis, Postmenopausal
Combined Use of Teriparatide and Raloxifene in Postmenopausal Women With Osteoporosis
The purpose of this study is to compare treatment with both teriparatide and raloxifene with teriparatide alone. The study will evaluate any side effects that may be associated with the two drugs and may help to determine whether…
- Trial name
- NCT00046137
- Testing
- teriparatide, raloxifene
- Where
- 13 sites in United States
- Sponsor
- Eli Lilly and Company
Osteoporosis
The Change of Bone Markers After Low Dose Alendronate in Postmenopausal Women With Bone Loss
High bone turnover with the bone resorption exceeding bone formation is a major mechanism of postmenopausal osteoporosis. Therefore, inhibition of bone resorption is a rational approach for the prevention.
- Trial name
- NCT00460057
- Testing
- Alendronate
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Eulji University Hospital
Osteoporosis, Osteopenia
A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density.
The purpose of this study is to determine whether in postmenopausal women with low bone mineral density, the mean percent change in total hip BMD in subjects receiving denosumab is not less than that observed in subjects…
- Trial name
- NCT00330460
- Testing
- Alendronate, Denosumab
- Volunteers
- 1,189 people
- Sponsor
- Amgen
Osteopenia, Generalized
Evaluate the Effect of Lifenol in Improving Bone Status in Postmenopausal Osteopenic Women
A Randomised, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Effect of Lifenol® in Improving Bone Status in Postmenopausal Osteopenic Women.
- Trial name
- NCT04004013
- Testing
- Lifenol®
- Where
- Ireland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Givaudan France Naturals
Osteoporosis Postmenopausal
Efficacy and Safety of Odanacatib (MK-0822) in Participants With Involutional Osteoporosis (MK-0822-022)
The purpose of this study is to assess the dose-response on the percent change from baseline in lumbar spine bone mineral density (BMD) at lumbar vertebrae 1 to 4 (L1- L4) when odanacatib (MK-0822) 10 mg, 25 mg, 50 mg or placebo…
- Trial name
- NCT00620113
- Testing
- Odanacatib, Vitamin D3, Calcium carbonate
- Volunteers
- 287 people
- Sponsor
- Merck Sharp & Dohme LLC
Low Bone Mineral Density, Postmenopausal Osteoporosis
Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density
The primary objective was to determine the effect of treatment with romosozumab versus placebo at month 12 on the percent change from baseline in bone mineral density (BMD) at the lumbar spine in postmenopausal women with low…
- Trial name
- NCT00896532
- Testing
- Alendronate, Teriparatide, Romosozumab
- Volunteers
- 419 people
- Sponsor
- Amgen
Postmenopause, Osteoporosis
PROPOSE Quality - PReOtact in Postmenopausal OStEoporosis - Quality of Life Study (FP-004-DE)
The objectives of the study are to describe the quality of life at the beginning of the Preotact® treatment and at the end of the observational period (Qualeffo-41 questionnaire) pain assessment at the beginning of the Preotact®…
- Trial name
- NCT00515593
- Testing
- Parathyroid hormone (PTH) (Preotact)
- Where
- Germany
- Volunteers
- 110 people
- Sponsor
- Nycomed
Osteopenia, Postmenopausal Osteopenia
Effect of Calcium and Vitamin D Supplementation With and Without Collagen Peptides in Postmenopausal Women With Osteopenia
Osteoporosis is undoubtedly one of the most common diseases affecting older individuals with debilitating consequences. Osteopenia, defined as T-score between -1 and -2.5, has also been associated with increased risk of…
- Trial name
- NCT03999775
- Testing
- Calcium, vitamin D and bioactive collagen peptides supplement, Calcium and vitamin D supplement
- Volunteers
- 51 people
- Sponsor
- Ioannis K. Triantafyllopoulos, MD,MSci,PhD
Osteoporosis, Postmenopausal
Effects of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis
The primary objective of this study is to demonstrate a reduction in the proportion of new vertebral fractures in postmenopausal women with osteoporosis following 3-years of treatment with 20 and 40 mcg/day of teriparatide plus…
- Trial name
- NCT00670501
- Testing
- teriparatide, Calcium Supplement, Vitamin D Supplement
- Where
- 17 sites in United States, Argentina and 15 more
- Volunteers
- 1,637 people
- Sponsor
- Eli Lilly and Company